Winton Group’s CG Oncology CGON Stock Holding History

Winton Group’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-8,669	Closed	-$225K	–	762
2025 Q2	$225K	Buy	+8,669	New	+$209K	0.01%	733

Other funds holding CGON

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Winton Group's CGON Position: Q3 2025 in Review

Winton Group sold out of CG Oncology (CGON) in Q3 2025, closing a stake of 8,669 shares — an estimated $225K sold.

Winton Group first reported a position in CGON in Q2 2025 and held it in 1 quarter. The position peaked at $225K in Q2 2025. 176 funds tracked by Wall St. Rank hold CGON as of Q3 2025.

Winton Group reported no remaining CG Oncology position as of Q3 2025 after selling out during the quarter.
Winton Group sold 8,669 CG Oncology shares in Q3 2025, an estimated $225K.
Winton Group first reported a position in CG Oncology in Q2 2025 and held it in 1 quarter.
Winton Group's CG Oncology position peaked at $225K in Q2 2025.
176 funds tracked by Wall St. Rank held CG Oncology as of Q3 2025.

Based on Winton Group's 13F filing for Q3 2025, filed 13 Nov 2025.